Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Tax Provisions (2017 - 2025)

Avalo Therapeutics (AVTX) has disclosed Tax Provisions for 9 consecutive years, with $11000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Tax Provisions rose 178.57% year-over-year to $11000.0, compared with a TTM value of $149000.0 through Sep 2025, up 1755.56%, and an annual FY2024 reading of $114000.0, up 714.29% over the prior year.
  • Tax Provisions was $11000.0 for Q3 2025 at Avalo Therapeutics, down from $16000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $114000.0 in Q4 2024 and bottomed at -$200000.0 in Q2 2021.
  • Average Tax Provisions over 5 years is $421.05, with a median of $8000.0 recorded in 2021.
  • Peak annual rise in Tax Provisions hit 1366.67% in 2024, while the deepest fall reached 275.0% in 2024.
  • Year by year, Tax Provisions stood at -$16000.0 in 2021, then surged by 150.0% to $8000.0 in 2022, then plummeted by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then crashed by 90.35% to $11000.0 in 2025.
  • Business Quant data shows Tax Provisions for AVTX at $11000.0 in Q3 2025, $16000.0 in Q2 2025, and $8000.0 in Q1 2025.